Home
About Us
Scientific Platforms
- ADCs
- Publications
Team
News
Contact

Search

Search
- Search

Home
About Us
Scientific Platforms
- ADCs
- Publications
Team
News
Contact

Home » Uncategorized » Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health

Uncategorized

Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health

by Mbio2018|Published September 1, 2018

https://projectreporter.nih.gov/project_info_description.cfm?aid=9623199&icde=51409496&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC&pball=

Project Number: 1R43CA228746-01A1

Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER

Manhattan BioSolutions establishes new laboratory space at the JLabs JNJ Innovation incubator in New York City

Published June 1, 2018

Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University

Published November 7, 2023

Manhattan BioSolutions Enters Into Collaboration Agreements with the NIH and Binghamton University to Develop Novel ADC

Collaboration with National Institutes of Health and Binghamton University to Develop Novel Antibody-Drug Conjugates for Pediatric Cancer New York City, New York […]

Published January 13, 2021

Manhattan BioSolutions to Present at the ACCESS CHINA Forum @JPM WEEK 2021

NEW YORK, NEW YORK, UNITED STATES, January 13, 2021 – Manhattan BioSolutions, Inc. (MABS), an emerging biotechnology company focused on the discovery […]

Previous post Manhattan BioSolutions has won prestigious Johnson & Johnson Innovation QuickFire Challenge Competition and award to receive free laboratory and office space at the newly open JLabs@NYC incubator in downtown Manhattan
Back to post list
Next post Manhattan BioSolutions establishes new laboratory space at the JLabs JNJ Innovation incubator in New York City